Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$18.10
-2.7%
$17.89
$13.30
$25.00
$434.64M1.114,906 shs3,399 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
+5.27%+3.51%-4.44%+9.78%-19.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
2.4794 of 5 stars
3.85.00.00.01.80.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
3.50
Strong Buy$45.00148.69% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$4.83M89.99$2.40 per share7.53$17.04 per share1.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$27.78MN/A0.00N/AN/AN/AN/AN/A7/30/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/A
9.33
9.33

Institutional Ownership

CompanyInstitutional Ownership
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.04%

Insider Ownership

CompanyInsider Ownership
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
10024.02 million22.75 millionNot Optionable

Recent News About These Companies

PureTech CEO Bharatt Chowrira steps down
PureTech Health CEO Bharatt Chowrira Resigns
PureTech Announces Leadership Transition
PureTech Announces Board Change
Leerink Partners Keeps Their Buy Rating on PureTech Health (PRTC)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
PureTech Health stock logo

PureTech Health NASDAQ:PRTC

$18.10 -0.51 (-2.72%)
As of 02:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.